Navigation Links
CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies
Date:4/3/2008

ise von Willebrand factor in the bloodstream(ii).

About Helixate(R) FS and Humate-P(R)

Helixate(R) FS is a recombinant version of the human factor VIII (FVIII) produced with the help of baby hamster kidney (BHK) cells. It is used to treat hemophilia A when there is a demonstrated deficiency of the above mentioned factor FVIII, a plasma clotting factor. Helixate(R) FS should be administered cautiously in patients with previous hypersensitivity to constituents of FVIII preparations or known sensitivity to mouse or hamster protein.

Helixate(R) FS should not be used to treat people with VWD since it does not contain the von Willebrand factor, the endogenous protein which is absent or defective in the VWD. For more information about von Willebrand disease, please visit http://www.allaboutbleeding.com.

Adverse events related to the use of Helixate (R) FS are generally minor. The most common events include injection-site reactions, dizziness and rash.

Humate-P(R) is a stable, purified, sterile, lyophilized concentrate of Antihemophilic Factor (Human) and von Willebrand Factor (vWF) (Human) complex used for the treatment of patients with classical hemophilia (hemophilia A) and VWD.

Humate-P(R) is usually tolerated without reaction. It should be administered with caution to patients with a known allergic reaction to constituents of the preparation. Cases of allergic reactions and rise in body temperature have been observed. Anaphylactic reactions can occur in rare instances. Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.

Humate-P(R) is made from human plasma and there is a theoretical risk that it may contain pathogens susceptible to cause diseases such as the hepatitis viruses, HIV and,
'/>"/>

SOURCE CSL Behring
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. CSL Behring Expands Into Middle East Market with Haemate(R) P
2. Siemens Completes Acquisition of Dade Behring
3. Siemens Receives EU Antitrust Clearance for Acquisition of Dade Behring
4. AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries
5. Pharsight Signs Two New DMX(R) License Customers
6. Siemens Signs Multi-Year Agreement With Cleveland Clinic to Deploy Enterprise-Wide Cardiology PACS
7. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
8. Cardiac Science Signs Letter of Intent With Misys Healthcare Systems to Connect With Their EMR Systems
9. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France
10. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
11. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  The Chicago Bears are excited to announce the ... in an effort to raise awareness of skin cancer. ... SPOT me™ skin cancer screenings at a preseason fan ... SPOT me™ is an educational campaign designed to inform ... of skin cancer, and encourages people to get screened ...
(Date:7/30/2014)... July 30, 2014   Wyle has ... Integrated Lifecycle Mission Support Services (FILMSS) contract awarded ... Under the terms of the contract, Wyle will ... Moffett Field, Calif. In particular, Wyle will provide ... development projects on the International Space Station and ...
(Date:7/30/2014)... Yuma, AZ (PRWEB) July 30, 2014 ... , State-of-the-art facility and complementary therapies brings comprehensive ... square foot, state-of-the-art Yuma Regional Cancer Center has ... since 2012, the program includes services such as ... laboratory, massage therapy, American Cancer Society Resource Center, ...
(Date:7/30/2014)... 30, 2014  AtheroNova Inc. (OTCBB: AHRO), a ... of compounds to safely regress atherosclerotic plaque and ... its partner, CardioNova, has accomplished first dosing of ... AtheroNova,s lead compound, AHRO-001.  This Phase 1b trial ... 1 safety trial completed in February 2014, in ...
Breaking Biology Technology:Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4
... (Nasdaq: BNVI ) today announced financial ... "Scientific development, regulatory progress and growth accurately characterize ... chairman and chief executive officer. "We successfully laid ... is essential for the successful approval and marketing ...
... Corporation (NYSE: SGP ) is scheduled to ... first quarter on Tuesday, April 21, 2009. At ... a conference call to review results for the 2009 ... and other members of management will host the conference ...
... LLC, and Burrill & Company Collaborating on Strategic ... 12 Developer Tower Investments, LLC ("Tower"), and ... ("Burrill") today announced a formal partnership with aims ... planned development and funding related to the "shovel-ready" ...
Cached Biology Technology:Bionovo Announces 2008 Highlights and Year-End Financial Results 2Bionovo Announces 2008 Highlights and Year-End Financial Results 3Bionovo Announces 2008 Highlights and Year-End Financial Results 4Bionovo Announces 2008 Highlights and Year-End Financial Results 5Bionovo Announces 2008 Highlights and Year-End Financial Results 6Bionovo Announces 2008 Highlights and Year-End Financial Results 7Bionovo Announces 2008 Highlights and Year-End Financial Results 8Bionovo Announces 2008 Highlights and Year-End Financial Results 9Bionovo Announces 2008 Highlights and Year-End Financial Results 10Elk Run Developers Announce Partnership with Leading Life Sciences Firm 2Elk Run Developers Announce Partnership with Leading Life Sciences Firm 3Elk Run Developers Announce Partnership with Leading Life Sciences Firm 4
(Date:7/30/2014)... major interest in neuroscience. A large number of ... of Wallerian degeneration: transcription factor activation, immune response, ... responses in the distal segment of the sciatic ... in gene expression between the proximal and distal ... from Nantong University, China used microarrays to analyze ...
(Date:7/30/2014)... spinal cord injury (SCI), traumatic brain injury (TBI) and ... has been learned over the past 30 years regarding ... regulate axon growth, but this large body of information ... Lemmon and his team from University of Miami in ... but a consensus is emerging that one contributing factor ...
(Date:7/30/2014)... 3,000 pieces is still in its infant stage. But ... of major significance. "Amazingly often, we are findingin addition ... that we found in Baltic amber," explained Bonn paleontologist ... comes from the Baltic Sea region, which is almost ... e.g., the coastal regions of Mecklenburg, Poland and Belarus. ...
Breaking Biology News(10 mins):Chinese mosquitos on the Baltic Sea 2
... stress a typical married couple feels during an ordinary half-hour ... from wounds by at least one day, a new study ... routinely hostile toward each other, the delay in that healing ... have major financial implications for medical centers and health care ...
... an AIDS vaccine, UCLA AIDS Institute researchers report the ... the infection in different ways. , Detailed in the ... ( http://jvi.asm.org ), the findings show that the body's ... determined. , The researchers followed the cases of male ...
... much more sophisticated visual system than previously thought, according ... which bees were able to solve complicated colour puzzles. ... of the most difficult challenges of vision - namely, ... by suggesting that bees solve this problem using their ...
Cached Biology News:Stress substantially slows human body's ability to heal 2Stress substantially slows human body's ability to heal 3UCLA scientists discover immune response to HIV differs, even in identical twins 2Bees solve complex colour puzzles 2
Rabbit Serum New Zealand or California Origin...
Collected from 8-12 week old New Zealand or Californian rabbits. Aseptically collected and processed to minimize hemolytic activity. Pricing: $60/unit for 1 - 10 units...
... , Customer Peptide Synthesis , Containing one Phospho-Amino Acid ... will be returned to customer conjugation of peptide to KLH protein ... Maintenance 102 days/each , Pre-immune bleed x1 ... , Test bleed (app. 5 ml) x1 /each ...
... collected off the clot fasted non-Swiss Albino mice of ... Anticoagulants: N-02: Citrate N-04: ... Potassium Oxalate N-10: EDTA (Na) N-03: ... CPD N-09: K3EDTA N-11: Heparin ...
Biology Products: